Axsome (AXSM) Total Business Assets

Graphic logo of Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics (AXSM) is demonstrating steady sales growth for its migraine and depression treatments, maintaining independence from macroeconomic cycles. The success of Auvelity and the expansion of therapeutic areas are creating positive momentum. The company's aggregate resources on the chart confirm financial strength, where 700.69 determines the current value of the metric. Operations are complemented by strict adherence to environmental standards and a responsible approach to industrial waste disposal.

Axsome Therapeutics (AXSM): Cumulative Company Assets from 07/04/2022 to 10/27/2026

Analytical breakdowns for Axsome Therapeutics Inc (AXSM)

- price and consensus price forecast:
Stock Quotes axsome.com|AXSM - Price Target Chart
- market capitalization data:
Market Capitalization Axsome Corp|AXSM - Enterprise Value
- book capitalization data:
Net Asset Value per Share Axsome Therapeutics|AXSM - Company Net Assets|Market Capitalization to Book Value Ratio axsome.com|AXSM - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Axsome Therapeutics|AXSM - Long-Term Debt to Equity|Current Liabilities to Capital Axsome Corp|AXSM - Company Aggregate Debts|Debts to Book Capitalization Axsome Corp
Fundamental valuation:AXSM, axsome.com
Finished products of Axsome Therapeutics, Inc.

Total assets represent the sum of all company resources, reverse-calculated via ROA to eliminate information gaps between quarterly reports. By analyzing fluctuations in total assets, an investor assesses capital management efficiency, which is critically important for Axsome Therapeutics (AXSM) when scaling sales of patented drugs for the therapy of depressive disorders and expanding its commercial presence in the CNS market.

Analysis of competing companies

BIIB (biogen.com) - Cumulative Company Assets|Aggregate Company Assets Neurocrine Biosciences, Inc. (NBIX)|Total Business Assets Regencell Bioscience Ltd|ACADIA Pharmaceuticals Inc - Company Total Assets|Company Assets Xenon Corp XENE|Cumulative Company Assets VKTX (Viking Therapeutics)|supernus.com - Company Total Assets|Aggregate Company Assets Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Aggregate Asset Value|Aggregate Company Assets HRMY|Biohaven Corp (BHVN) - Company Assets|AMLX (Amylyx Pharmaceuticals) - Company Total Assets|Company Total Assets trevitherapeutics.com (TRVI)|Cumulative Company Assets Praxis Precision Medicines, Inc. PRAX|Total Business Assets AVXL (Anavex)|Aggregate Company Assets CBLL|Prothena - Company Total Asset Base|ALEC (Alector Therapeutics) - Aggregate Company Assets|ANNX: Company Assets|OMER (omeros.com) - Aggregate Company Assets|Neurogene Inc (NGNE) - Cumulative Company Assets|Company Total Assets ACIU (AC Immune Corp)|Company Assets Voyager Corp (VYGR)|Neumora Therapeutics (NMRA) - Cumulative Company Assets|Aggregate Asset Value scilexholding.com SCLX|Cumulative Company Assets Tevogen Bio (TVGN)|Aggregate Business Assets Alpha Cognition Inc ACOG|Company Total Assets Cognition Therapeutics, Inc. (CGTX)|IKT - Aggregate Asset Value|Company Total Assets SAVA|ASRT (Assertio) - Company Assets|COYA - Aggregate Company Assets|Aggregate Asset Value VistaGen Therapeutics Inc|Company Total Assets OVID|Company Total Assets ABOS (Acumen Pharmaceuticals, Inc)|CervoMed Inc. (CRVO) - Aggregate Company Assets|Total Asset Value of Company Alterity Therapeutics Ltd. ATHE|CLNN (Clene Nanomedicine) - Company Total Assets|PepGen Inc. (PEPG) - Company Assets|JUNS: Cumulative Company Assets|Company Total Assets Relmada Corp|Annovis Bio, Inc. (ANVS) - Cumulative Company Assets|Aggregate Business Assets Grace Tx|AIFF (Firefly Neuroscience) - Company Total Assets|Company Total Asset Base anewmeds.com (KLTO)|NeuroSense Therapeutics Ltd. - Company Total Assets|Reviva Pharmaceuticals, Inc. - Cumulative Company Assets|Aggregate Company Assets MTVA (MetaVia, Inc.)|NRXS - Company Total Asset Base|HSDT: Company Total Assets|Company Total Assets Passage Bio|Cumulative Company Assets Neuphoria Therapeutics, Inc. (NEUP)|Total Business Assets NERV|ATHA (Athira Pharma, Inc.) - Aggregate Company Assets|Company Total Asset Base ADXN (addextherapeutics.com)|Alzamend Neuro - Aggregate Company Assets|Cyclerion Therapeutics Inc. - Cumulative Company Assets|Protagenic (PTIX) - Aggregate Company Assets|KTTA - Total Business Assets|Company Total Assets CRGT|Company Assets avenuetx.com|BCLI (BrainStorm Cell Therapeutics) - Cumulative Company Assets|Company Total Assets CARA|Chromocell Therapeutics Corporation (CHRO) - Aggregate Company Assets|Aggregate Asset Value ELYM (eliemtx.com)|ITCI: Aggregate Company Assets|Company Assets longboardpharma.com LBPH|Marinus Pharmaceuticals, Inc. - Company Total Assets|NKGen Biotech Inc (NKGN) - Company Total Assets|Cumulative Company Assets NeuroBo|SAGE (Sage Therapeutics Inc) - Total Business Assets|SNPX: Aggregate Company Assets|Company Total Asset Base TRVN|Vigil Neuroscience - Aggregate Company Assets|Company Assets WENA (anewmeds.com)|Cerevel - Aggregate Company Assets